Literature DB >> 29129789

Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.

Yuanyuan Liu1, Linan Qiao1, Sipei Zhang1, Guoyun Wan1, Bowei Chen1, Ping Zhou1, Ning Zhang2, Yinsong Wang3.   

Abstract

In the present study, a dual pH-responsive multifunctional nanoparticle system was designed for combining immunotherapy and chemotherapy to treat breast cancer through targeting immune cells and cancer cells. A proven anti-tumor immune regulator, R848, was encapsulated with poly(L-histidine) (PHIS) to form PHIS/R848 nanocores. Doxorubicin (DOX) was conjugated to hyaluronic acid (HA) through an acid-cleavable hydrazone bond linkage to synthesize polymeric prodrug HA-DOX, which was subsequently coated outside PHIS/R848 nanocores to form HA-DOX/PHIS/R848 nanoparticles. Ionization of PHIS around pH 6.5 (a pH value close to that of tumor microenvironment) switched the nature of this material from hydrophobic to hydrophilic, and thus triggered the release of R848 to exert immunoregulatory action. The rupture of hydrazone bond in HA-DOX at about pH 5.5 (pH of endo/lysosomes) accelerated the release of DOX to exert cytotoxic effects. In immune cells, PHIS/R848 nanocores exhibited strong immunoregulatory activities similar to those induced by free R848. In breast cancer cells overexpressing CD44, HA-DOX was specially internalized by CD44-mediated endocytosis and significantly inhibited the cell growth. In 4T1 tumor-bearing mice, HA-DOX/PHIS/R848 nanoparticles showed excellent tumor-targeting ability and remarkably inhibited the tumor growth by regulating tumor immunity and killing tumor cells. In summary, this multifunctional nanoparticle system could deliver R848 and DOX respectively to tumor microenvironment and breast cancer cells to achieve synergistic effects of immunotherapy and chemotherapy against breast cancer. STATEMENT OF SIGNIFICANCE: Combination of immunotherapy and chemotherapy is becoming a promising new treatment for cancer. The major challenge is to target cancer and immune cells simultaneously and specifically. In this study, a dual pH-responsive multifunctional nanoparticle system based on poly(L-histidine) and hyaluronic acid was designed for co-loading R848 (immune-regulator) and doxorubicin (chemotherapeutic drug) through different encapsulation modes. By responding to the acidic pHs of tumor microenvironment and intracellular organelles, this multifunctional nanoparticle system could release R848 extracellularly and deliver DOX targetedly to breast cancer cells, thus achieving synergistic effects of immunotherapy and chemotherapy against breast cancer.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Chemotherapy; Immunotherapy; Nanoparticle; Targeting

Mesh:

Substances:

Year:  2017        PMID: 29129789     DOI: 10.1016/j.actbio.2017.11.010

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  31 in total

1.  Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer.

Authors:  Qin Gxin Mu; Guanyou Lin; Mike Jeon; Hui Wang; Fei-Chien Chang; Richard A Revia; John Yu; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2021-09-07       Impact factor: 31.041

2.  Fucoidan with three functions extracted from Sargassum aquifolium integrated rice-husk synthesis dual-imaging mesoporous silica nanoparticle.

Authors:  Zui-Harng Lee; Meng-Feng Lee; Jung-Huang Chen; Min-Hsuan Tsou; Zhi-Yuan Wu; Cheng-Zhang Lee; Yu-Ya Huang; Showe-Mei Lin; Hsiu-Mei Lin
Journal:  J Nanobiotechnology       Date:  2022-06-22       Impact factor: 9.429

Review 3.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.

Authors:  Xiaopin Duan; Christina Chan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

4.  Self-Assembling pH-Responsive Nanoparticle Platform Based on Pectin-Doxorubicin Conjugates for Codelivery of Anticancer Drugs.

Authors:  Yinghua Tao; Dan Zheng; Jingyang Zhao; Kefeng Liu; Jing Liu; Jiandu Lei; Luying Wang
Journal:  ACS Omega       Date:  2021-04-08

5.  Dual targeted and pH-responsive gold nanorods with improved chemotherapy and photothermal ablation for synergistic cancer treatment.

Authors:  Jing Wang; Hui Wang; Lin Yan; Zhiqiang Hu; Xiuli Wu; Fengmei Li
Journal:  RSC Adv       Date:  2019-02-14       Impact factor: 4.036

Review 6.  Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights.

Authors:  María Vallet-Regí; Montserrat Colilla; Isabel Izquierdo-Barba; Miguel Manzano
Journal:  Molecules       Date:  2017-12-25       Impact factor: 4.411

Review 7.  Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy.

Authors:  Dhruv Varshney; Sherry Yue Qiu; Tyler P Graf; Kevin J McHugh
Journal:  AAPS J       Date:  2021-06-28       Impact factor: 4.009

Review 8.  Overcoming biological barriers to improve solid tumor immunotherapy.

Authors:  Anvay Ukidve; Katharina Cu; Ninad Kumbhojkar; Joerg Lahann; Samir Mitragotri
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

Review 9.  Nanotechnology for Cancer Therapy Based on Chemotherapy.

Authors:  Chen-Yang Zhao; Rui Cheng; Zhe Yang; Zhong-Min Tian
Journal:  Molecules       Date:  2018-04-04       Impact factor: 4.411

10.  Controllable Drug Delivery by Na+/K+ ATPase α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer.

Authors:  Yayan Yang; Qian Feng; Chuanfeng Ding; Wei Kang; Xiufeng Xiao; Yongsheng Yu; Qian Zhou
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.